DMOG

For research use only. Not for use in humans.

目录号:S7483 别名: Dimethyloxalylglycine

DMOG Chemical Structure

CAS No. 89464-63-1

DMOG (Dimethyloxalylglycine)是α-酮戊二酸辅助因子的拮抗剂和HIF prolylhydroxylase的抑制剂,它使HIF-1α蛋白在核内稳定并积累,是HIF-1α的激动剂。DMOG 可增加自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 987.58 现货
RMB 794.43 现货
RMB 2678.13 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的DMOG发表文献21篇:

产品安全说明书

Hydroxylase抑制剂选择性比较

生物活性

产品描述 DMOG (Dimethyloxalylglycine)是α-酮戊二酸辅助因子的拮抗剂和HIF prolylhydroxylase的抑制剂,它使HIF-1α蛋白在核内稳定并积累,是HIF-1α的激动剂。DMOG 可增加自噬。
靶点
HIF prolyl hydroxylase [1]
()
体外研究

DMOG在微粒体系统中仅有很低的活性,但在完整细胞中可强烈抑制羟基脯胺酸合成。[1]在HPASMC中,DMOG通过抑制脯氨酰羟化酶降低FGF-2诱导的组织和cyclin A表达。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human SR cell NHPGR|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInTfXRKdmirYnn0bY9vKG:oIHj1cYFvKFOUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND61O|k1PiEQvF2= MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human LB996-RCC cell M3n6dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXfwU2lIUW6qaXLpeIlwdiCxZjDoeY1idiCOQkm5Ok1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[4O|ch|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human LOUCY cell NX:xSFVoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4X1R2lvcGmkaYTpc44hd2ZiaIXtZY4hVE:XQ2mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4{PDl|IN88US=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human KS-1 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX6wRlRvUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOjV3NzFOwG0> NV3LbmR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human U-698-M cell MlHtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2fDWmlvcGmkaYTpc44hd2ZiaIXtZY4hXS14OUitUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{NjN|ME[g{txO M3TZZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human A3-KAW cell M{DYO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPUXGxmUW6qaXLpeIlwdiCxZjDoeY1idiCDMz3LRXch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS56MUe0JO69VQ>? MmL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human BL-70 cell M1;TTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGJNNTdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuPVQzOyEQvF2= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human DMS-273 cell MmLxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHaTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvQTZ3IN88US=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human CAL-39 cell NGPnSW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnXTno{UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5|Mke3JO69VQ>? MmqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human KYSE-410 cell MnH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDuT|BlUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVQyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkixPVch|ryP NHrZ[FY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human YT cell NF7vVJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYnGRlNWUW6qaXLpeIlwdiCxZjDoeY1idiC\VDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKzMlM6QDRizszN NGDJV4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human LC-2-ad cell M{[yeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MULJcohq[mm2aX;uJI9nKGi3bXHuJGxENTJvYXSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE42PTd|IN88US=> NUfZR|AzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human COR-L105 cell M1XZc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInYO|ZKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjZwNESzOkDPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human CAL-12T cell MnHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOk42PTB{IN88US=> M3HRVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human KU812 cell NWq0OJF{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHPqbWtKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPDV5OTFOwG0> M{OwRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human OPM-2 cell NILW[m1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mm[yTY5pcWKrdHnvckBw\iCqdX3hckBQWE1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlgzOjdizszN M3HSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human SW982 cell NV:1[oVXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4PNR2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{44ODB5IN88US=> Ml;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human HH cell NX7Jd|c6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\5c2lvcGmkaYTpc44hd2ZiaIXtZY4hUEhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND6wNlM2KM7:TR?= M3iwR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human RS4-11 cell NGSxfZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHf2SHRKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjF6ME[g{txO Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human BEN cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJGJGViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN4LkixPFch|ryP M2LWRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human CCRF-CEM cell NGTaO25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGNEWkZvQ1XNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|cvPzd{OTFOwG0> NHmxSJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OjNyOT:nQnNCVkeHUkyvZV4>
human EW-13 cell NHvqTmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{muNFQ5OSEQvF2= MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human NCI-H2228 cell NUXqNmRMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M163emlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDJwOEG4JO69VQ>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human KE-37 cell NFjEO|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEfR[2VKdmirYnn0bY9vKG:oIHj1cYFvKEuHLUO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFMvOjlzNTFOwG0> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5NlMxQS9pPmPBUmdGWjxxYU6=
human A4-Fuk cell M3\YUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3rlVWlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvODN4NDFOwG0> NYDWVohDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human MZ1-PC cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfJXpZKdmirYnn0bY9vKG:oIHj1cYFvKE2cMT3QR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2Njl6OEig{txO MlzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI{ODlxJ{7TRW5ITVJ:L3G+
human MLMA cell NH64UFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vIbmlvcGmkaYTpc44hd2ZiaIXtZY4hVUyPQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS2MlMzQTJizszN NV6z[HVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ|MEmvK|5USU6JRWK8M4E,
human EB-3 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXSeGhZUW6qaXLpeIlwdiCxZjDoeY1idiCHQj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFkvPTd7MjFOwG0> M1;rO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzOzB7Lze+V2FPT0WUPD;hQi=>
human 293T cells  NVXqSmpKTnWwY4Tpc44h[XO|YYm= M4PFdlIvPSCvTR?= NWDM[phoUW6qaXLpeIlwdiCxZjDKUWpFOi2vZXTpZZRm\CCKM1uzOkBl\W2ndHj5cIF1cW:wIHnuJIh2dWGwIEK5N3Qh[2WubIOgZZQhOi53IH3N NUGzemZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOVkyPjdpPkG5N|U6OTZ5PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HIF-1α; 

PubMed: 29555474     


DMOG time-dependently increases the expression of HIF-1α. AML12 cells were treated with DMOG for indicated time. Protein level of HIF-1α was detected by Western blotting. β-actin was used as internal control. Signal intensity was analyzed using Image J software and expressed as mean ± SEM. Shown is the representative of at least 3 repeat experiments. *P < 0.05 v. s. DMSO group.

p-CHK1 / CHK1 / p-p53 / p53 / p-CHK2 / CHK2 / p-ATM / ATM; 

PubMed: 22797300     


HeLa cells were pretreated with DMOG for 4 hours, followed by NCS treatment as indicated. Western blots were performed with indicated antibodies. 

WNT11 / HIF-2α ; 

PubMed: 26861754     


(E,F) Induction of Wnt11 by increasing concentrations of DMOG in MDA-MB-231 cells (E) and 4T1 cells (F).

29555474 22797300 26861754
Immunofluorescence
HIF1α; 

PubMed: 28955984     


HeLa cells grown in the presence or absence of 1 mM DMOG were immunostained to visualize HiF1α localization. 

28955984
体内研究

在小鼠局部缺血的骨骼肌中,DMOG抑制內源性HIF失活,诱导血管新生。[2]在高血脂症大鼠体内,通过DMOG上调的缺氧诱导因子1a能够增强缺血后处理的心脏保护作用。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[3]

- 合并
  • Cell lines: VSMC细胞
  • Concentrations: ~100 μM
  • Incubation Time: 72-96 小时
  • Method:

    为分析DNA合成作为细胞增殖的指数,VSMC细胞以5000个每平方厘米的密度接种在48孔板培养基中,孵育过夜,除去血清(1%FCS)处理24小时。复制的孔板储存−70°C 作为基线(第0天)细胞计数,含有或者不含有生长因子的新鲜培养基加入孔板中,在20%或5%的氧气中孵育72-96小时。第0,3,4天,通过在含有荧光染料的缓冲液中裂解细胞测定细胞数,其自身具有很弱的荧光性,但与DNA或RNA结合时会增强荧光。细胞数目的定量是通过比较样品的荧光与已知细胞数目的标准曲线比较来测定的。


    (Only for Reference)
动物实验:

[2]

- 合并
  • Animal Models: 小鼠(C57Bl6)
  • Dosages: 8毫克在0.5毫升生理盐水中
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 35 mg/mL (199.84 mM)
Water 35 mg/mL (199.84 mM)
Ethanol '35 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 175.14
密度 1.246 g/mL
化学式

C6H9NO5

CAS号 89464-63-1
储存条件 粉状
溶于溶剂
别名 Dimethyloxalylglycine

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Hydroxylase Signaling Pathway Map

相关Hydroxylase产品

Tags: 购买DMOG | DMOG供应商 | 采购DMOG | DMOG价格 | DMOG生产 | 订购DMOG | DMOG代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID